It is widely recognized that TrkB activation is a significant target in cancer treatment [92, 93], with TrkB activation driving the proliferation and survival of cancer stem-like cells [36, 146], with differential effects on immune cells, versus melatonin and GR, as indicated in Table 1. This evidence concerns the gene NTRK2 and cancer.